Status:
UNKNOWN
Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography
Lead Sponsor:
BSP Biological Signal Processing Ltd.
Conditions:
Ischemic Heart Disease
Eligibility:
FEMALE
Phase:
PHASE4
Brief Summary
The purpose of this study is to verify the efficiency of the HyperQ technology compared with standard ECG analysis in detecting exercise induced ischemia in women who are referred to coronary angiogra...
Detailed Description
Cardiovascular disease (CVD) is the leading cause of mortality in women. In fact, CVD is responsible for a third of all deaths of women worldwide and half of all deaths of women over 50 years of age i...
Eligibility Criteria
Inclusion
- A woman who was referred to angiography.
- A woman who is able (i.e. no contraindications) to perform an exercise stress test
- A woman who signed an informed consent form.
Exclusion
- Contraindications for an exercise test
- Wolff-Parkinson-White (pre-excitation) syndrome.
- Left Bundle branch block, Complete Right bundle branch block or QRS duration \> 120 ms, change in QRS morphology during exercise
- Atrial Fibrillation or significant ventricular arrhythmia
- Treatment with Digoxin
- Pacemaker
- Having taken beta blockers within 24 hours before the exercise test
- Pregnancy or suspected pregnancy
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00850486
Start Date
August 1 2008
End Date
March 1 2010
Last Update
February 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaare Zedek Medical Center
Jerusalem, Israel